A Pilot Study of Full Dose Gemcitabine and Hypofractionated Stereotactic Radiosurgery in the Treatment of Unresectable Pancreatic Cancer
This is a single arm, open-label pilot study of Cyberknife plus Gemcitabine in 10 patients
with locally advanced pancreatic cancer who have not received prior local or systemic
therapy for their pancreatic cancer.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To demonstrate that radiation treatments can be reproduced as determined by evaluation of the prescription isodose curves
10 days
Yes
Michael J Pishvaian, MD, PhD
Principal Investigator
Georgetown University
United States: Institutional Review Board
2009-169
NCT01051284
November 2009
March 2012
Name | Location |
---|---|
Georgetown University Medical Center | Washington, District of Columbia 20007 |